This report was our free report of the day on a previous date — it has since expired.

Today's free report is available: PXED 10-Q — PXED Q3 FY26: Enrollment +2.2%, revenue +0.9%, but $47M share-comp surge cuts …

Sign up free to read 3 full reports/month

Get notified when PETS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Going Concern (new) — Substantial doubt raised due to cash decline from $54.7M to $21.4M, 21% revenue decline, negative operating cash flow, and recurring losses; management's mitigation plan deemed probable of alleviating doubt.
  • Goodwill Impairment (new) — Full $26.7M goodwill write-off in Q1 FY2026 after quantitative test showed carrying value exceeded fair value, triggered by sustained revenue declines and stock price deterioration.
  • Material Weakness (worsened) — Three material weaknesses remediated (Income Taxes, Complex Accounting, Tone at the Top) during FY2026, reducing total count from six to three; three remain unremediated (Sales Taxes, ITGCs, Revenue Recognition).
  • Auditor Change (new) — Baker Tilly replaced RSM US LLP as auditor for FY2026; RSM had served from 2007 to 2025.
NASDAQ: PETS PETMED EXPRESS INC 10-K

PetMed Express posts $57.3M loss on $26.7M goodwill write-off, 21% sales decline

Filed June 2, 2026 · Period ending March 31, 2026 · Compared to 10-K Oct 14, 2025 · ~2 min read

Key Changes

  • high

    Net loss widened to $57.3M from $6.3M, driven by $26.7M goodwill impairment (entire balance from PetCareRx acquisition) and 21% revenue decline to $179M. Operating loss widened 3735% to $58.7M, but net loss widened only 814% due to $6.1M below-the-line improvement (non-operating/other +$371K, income tax +$5.8M).

    MD&A: Financial Results verify on EDGAR →
  • high

    Management disclosed substantial doubt about ability to continue as going concern due to cash decline from $54.7M to $21.4M, negative operating cash flow of $28.4M, and recurring losses. Mitigation plan (advertising optimization, expense cuts, reduced capex) deemed probable of alleviating doubt.

    Notes: Going Concern verify on EDGAR →
  • high

    Company pivoted from omnichannel expansion (Amazon marketplace, retail licensing, Dutch Pet telemedicine partnership) to pharmacy-centric B2B strategy. All prior multichannel initiatives removed from disclosure; new focus on white-label pharmacy fulfillment for partners and veterinary clinics.

    Business: Strategic Direction verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Partner

Trade PETS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify